Dexmedetomidine + Chloral hydrate
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Procedural Sedation
Conditions
Procedural Sedation
Trial Timeline
Aug 1, 2009 → May 1, 2011
NCT ID
NCT00464451About Dexmedetomidine + Chloral hydrate
Dexmedetomidine + Chloral hydrate is a phase 2 stage product being developed by Pfizer for Procedural Sedation. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00464451. Target conditions include Procedural Sedation.
What happened to similar drugs?
1 of 1 similar drugs in Procedural Sedation were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00464451 | Phase 2 | Withdrawn |
Competing Products
2 competing products in Procedural Sedation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl | Eisai | Approved | 35 |
| AQUAVAN® (fospropofol disodium) Injection | Eisai | Phase 2/3 | 38 |